文献速递前列腺癌

石榴在前列腺癌中的研究综述

A review of pomegranate in prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2017-04-25

BACKGROUND: Preclinical studies showing that pomegranate juice and its components inhibit prostate cancer led to multiple clinical trials to determine whether pomegranate products could slow the growth of prostate cancer.…

要点

  • 石榴汁和提取物在生化复发患者中安全,但大型安慰剂对照试验未显著改善结局。
  • MnSOD AA基因型生化复发患者可能对石榴的抗氧化作用有积极反应。
  • 含31.25%石榴提取物的多组分食品补充剂在II期研究中显示延缓PSA升高的前景。

核心结论

  • 石榴汁和提取物是安全的,但在大型安慰剂对照试验中未显著改善生化复发患者的结局。
  • MnSOD AA基因型的生化复发患者亚组似乎对石榴治疗的抗氧化作用有积极反应。
  • 100%石榴产品在新辅助患者和mCRPC患者中的II期试验结果为阴性。
  • 多组分食品补充剂在主动监测和生化复发患者的II期研究中显示有前景的结果。

研究设计与样本

  • 本综述总结了石榴在前列腺癌中的临床前数据并讨论了临床试验结果。
  • 试验针对主动监测患者、新辅助患者、局部治疗后生化复发患者以及转移性去势抵抗性前列腺癌患者。

主要发现

  • 在生化复发患者中,石榴汁和提取物的早期II期试验均显示PSA倍增时间显著延长,并确认了石榴产品的安全性。
  • 一项安慰剂对照III期试验确定石榴提取物未显著延长生化复发患者的PSADT。
  • 预设亚组分析显示MnSOD AA基因型患者在前列腺癌提取物组显示更长的PSADT延长。
  • 在新辅助人群中,大型试验显示石榴组较安慰剂组尿石素A显著增加,8-羟基-2-脱氧鸟苷非显著降低。
  • 含31.25%石榴提取物的多组分食品补充剂的随机临床试验显示,在主动监测和生化复发男性中,食品补充剂组较安慰剂组PSA升高显著减缓。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preclinical studies showing that pomegranate juice and its components inhibit prostate cancer led to multiple clinical trials to determine whether pomegranate products could slow the growth of prostate cancer. This review summarizes the preclinical data and discusses the results of the clinical trials. METHODS: Trials targeted patients on active surveillance, neoadjuvant patients, patients with biochemical recurrence (BCR) following local therapy for prostate cancer, and patients with metastatic castration-resistant prostate cancer (mCRPC). RESULTS: In the BCR patient population, early phase II trials of both pomegranate juice and extract showed significant lengthening of PSA doubling time (PSADT), and confirmed the safety of pomegranate products. While a placebo-controlled phase III trial determined that pomegranate extract did not significantly prolong PSADT in BCR patients, a preplanned subset analysis of patients with the manganese superoxide dismutase (MnSOD) AA genotype showed greater PSADT lengthening on the pomegranate extract arm. In the neoadjuvant population, a large trial demonstrated a significant increase in urolithin A and a non-significant reduction in 8-hydroxy-2-deoxyguanosine, a marker of oxidation in prostate cancer tissue, on the pomegranate arm vs the placebo arm. In addition, a randomized clinical trial of a polyphenol-rich multicomponent food supplement that included a 31.25% pomegranate extract found significant slowing of PSA increase in the food supplement arm vs placebo in men on active surveillance and those experiencing BCR. CONCLUSIONS: Pomegranate juice and extract are safe but did not significantly improve outcomes in BCR patients in a large placebo-controlled trial. However a subset of BCR patients with the MnSOD AA genotype appear to respond positively to the antioxidant effects of pomegranate treatment. Phase II trials of 100% pomegranate products in neoadjuvant patients and patients with mCRPC were negative. A multicomponent food supplement showed promising results in a phase II study in active surveillance and BCR patients.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Paller CJ, Pantuck A, Carducci MA, et al. A review of pomegranate in prostate cancer. Prostate Cancer Prostatic Dis. 2017. PMID: 28440320. doi:10.1038/pcan.2017.19

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。